



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Fecal Analysis in the Diagnosis of Intestinal Dysbiosis

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 556

BCBSA Reference Number: 2.04.26 (For Plan internal use only)

Related Policies

- Fecal Calprotectin #[329](#)
- Fecal Microbiota Transplantation #[682](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Fecal analysis of the following components used as a diagnostic test for the evaluation of intestinal dysbiosis, irritable bowel syndrome, malabsorption or small intestinal overgrowth of bacteria is **INVESTIGATIONAL**:

- Triglycerides
- Chymotrypsin
- Iso-butyrate, iso-valerate, and n-valerate
- Meat and vegetable fibers
- Long-chain fatty acids
- Cholesterol
- Total short-chain fatty acids
- Levels of Lactobacilli, bifidobacteria, and *E coli* and other "potential pathogens," including *Aeromonas*, *Bacillus cereus*, *Campylobacter*, *Citrobacter*, *Klebsiella*, *Proteus*, *Pseudomonas*, *Salmonella Shigella*, *S. aureus*, *Vibrio*
- Identification and quantitation of fecal yeast (including *C. albicans*, *C. tropicalis*, *Rhodotorula*, and *Geotrichum*)
- N-butyrate
- Beta-glucuronidase
- pH
- Short--chain fatty acid distribution (adequate amount and proportions of the different short-chain fatty acids reflect the basic status of intestinal metabolism)
- Fecal secretory IgA.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is not a covered service.
Commercial PPO and Indemnity	This is not a covered service.
Medicare HMO BlueSM	This is not a covered service.
Medicare PPO BlueSM	This is not a covered service.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

CPT Codes

There is no specific CPT code for this service.

Description

Fecal Markers of Dysbiosis

Laboratory analysis of both stool and urine has been investigated as markers of dysbiosis. Commercial laboratories may offer testing for comprehensive panels or individual components of various aspects of digestion, absorption, microbiology, and metabolic markers. Representative components of fecal dysbiosis testing are summarized in Table 1.

Table 1. Components of the Fecal Dysbiosis Marker Analysis

Markers	Analytes
Digestion	<ul style="list-style-type: none"> Triglycerides Chymotrypsin Iso-butyrate, iso-valerate, and n-valerate Meat and vegetable fibers
Absorption	<ul style="list-style-type: none"> Long-chain fatty acids Cholesterol Total fecal fat Total short-chain fatty acids
Microbiology	<ul style="list-style-type: none"> Levels of Lactobacilli, bifidobacteria, and Escherichia coli and other "potential pathogens," including Aeromonas, Bacillus cereus, Campylobacter, Citrobacter, Klebsiella, Proteus, Pseudomonas, Salmonella, Shigella, Staphylococcus aureus, and Vibrio Identification and quantitation of fecal yeast (including Candida albicans, Candida tropicalis, Rhodotorula, and Geotrichum) (optional viral and/or parasitology components)
Metabolic	<ul style="list-style-type: none"> N-butyrate (considered key energy source for colonic epithelial cells) β-glucuronidase pH

	<ul style="list-style-type: none"> Short-chain fatty acid distribution (adequate amount and proportions of the different short-chain fatty acids reflect the basic status of intestinal metabolism)
Immunology	<ul style="list-style-type: none"> Fecal secretory immunoglobulin A (as a measure of luminal immunologic function) Calprotectin^a

^a Fecal calprotectin as a stand-alone test is addressed in policy #[329](#).

A related topic, fecal microbiota transplantation, the infusion of intestinal microorganisms to restore normal intestinal flora, is addressed in policy #[682](#). Fecal microbiota transplantation has been rigorously studied for the treatment of patients with recurrent *Clostridioides difficile* infection.

Summary

Intestinal dysbiosis may be defined as a state of disordered microbial ecology that is believed to cause disease. Laboratory analysis of fecal samples is proposed as a method of identifying individuals with intestinal dysbiosis and other gastrointestinal disorders.

Summary of Evidence

For individuals with gastrointestinal conditions such as suspected intestinal dysbiosis, irritable bowel syndrome (IBS), malabsorption, or small intestinal bacterial overgrowth who receive fecal analysis testing, the evidence includes several cohort and case-control studies comparing fecal microbiota in patients who had a known disease with healthy controls. The relevant outcomes are test validity, symptoms, and functional outcomes. The available retrospective cohort studies on fecal analysis have suggested that some components of the fecal microbiome and inflammatory markers may differ across patients with IBS subtypes. No studies were identified on the diagnostic accuracy of fecal analysis versus another diagnostic approach or that compared health outcomes in patients managed with and without fecal analysis tests. No studies were identified that directly informed the use of fecal analysis in the evaluation of intestinal dysbiosis, malabsorption, or small intestinal bacterial overgrowth. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
1/2024	Annual policy review. References updated. Policy statements unchanged.
2/2023	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
2/2022	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
2/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
2/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2017	Annual policy review. New references added.
3/2015	Annual policy review. New references added.
5/2014	Annual policy review. New references added.
4/2013	Annual policy review. New references added.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
10/2011	Reviewed - Medical Policy Group - GI, Nutrition and Organ Transplantation. No changes to policy statements.
5/2011	New policy effective 5/2011 describing ongoing non-coverage.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)
[Managed Care Guidelines](#)
[Indemnity/PPO Guidelines](#)
[Clinical Exception Process](#)
[Medical Technology Assessment Guidelines](#)

References

1. Emmanuel A, Landis D, Peucker M, et al. Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome. *Frontline Gastroenterol*. Oct 2016; 7(4): 275-282. PMID 27761231
2. Genova Diagnostics. 2023; <https://www.gdx.net/tests/prep/gi-stool-profiles>. Accessed October 23, 2023.
3. Goepf J, Fowler E, McBride T, et al. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. *Glob Adv Health Med*. May 2014; 3(3): 9-15. PMID 24891989
4. Jeffery IB, Das A, O'Herlihy E, et al. Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. *Gastroenterology*. Mar 2020; 158(4): 1016-1028.e8. PMID 31843589
5. Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. *J Gastroenterol*. Dec 2012; 47(12): 1298-307. PMID 22576027
6. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. *PLoS One*. Jan 27 2011; 6(1): e16393. PMID 21297998
7. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut*. May 2011; 60(5): 631-7. PMID 21209126
8. Langhorst J, Eisenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. *Am J Gastroenterol*. Jan 2008; 103(1): 162-9. PMID 17916108
9. Smalley W, Falck-Ytter C, Carrasco-Labra A, et al. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). *Gastroenterology*. Sep 2019; 157(3): 851-854. PMID 31302098
10. Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. *Gastroenterology*. Oct 2020; 159(4): 1526-1532. PMID 32679220